MedTrace Logo

NPI-002 Intravitreal Implant for the Delay of Cataract Progression

NCT05026632 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-04-13

No results posted yet for this study

Summary

This study will examine the safety and efficacy NPI-002 intravitreal implants post vitrectomy.

Conditions

  • Cataract

Interventions

DRUG

NPI-002 Intravitreal Implant

Implant inserted during vitrectomy.

Sponsors & Collaborators

  • Nacuity Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Jami R Kern, PhD · Nacuity Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-27
Primary Completion
2026-09-30
Completion
2026-09-30

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05026632 on ClinicalTrials.gov